AI Article Synopsis

  • Researchers sequenced genomes of various Escherichia coli strains, including types that produce Shiga toxin, and found 39 plasmids containing virulence genes.
  • Some plasmids were linked to antibiotic resistance against multiple drug classes and heavy metals, with two plasmids showing resistance to six different types of antibiotics.
  • The study suggests that plasmids carrying these resistance and virulence traits can circulate widely among different E. coli serotypes, regardless of their origins.

Article Abstract

The genomes of a diverse set of Escherichia coli, including many Shiga toxin-producing strains of various serotypes were determined. A total of 39 plasmids were identified among these strains, and many carried virulence or putative virulence genes of Shiga toxin-producing E. coli strains, virulence genes for other pathogenic E. coli groups, and some had combinations of these genes. Among the novel plasmids identified were eight that carried resistance genes to aminoglycosides, carbapenems, penicillins, cephalosporins, chloramphenicol, dihydrofolate reductase inhibitors, sulfonamides, tetracyclines and resistance to heavy metals. Two of the plasmids carried six of these resistance genes and two novel IncHI2 plasmids were also identified. The results of this study showed that plasmids carrying diverse resistance and virulence genes of various pathogenic E. coli groups can be found in E. coli strains and serotypes regardless of the isolate's source and therefore, is consistent with the premise that these mobile elements carrying these traits may be broadly disseminated among E. coli.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.plasmid.2015.12.001DOI Listing

Publication Analysis

Top Keywords

shiga toxin-producing
12
coli strains
12
plasmids identified
12
virulence genes
12
escherichia coli
8
strains serotypes
8
genes pathogenic
8
pathogenic coli
8
coli groups
8
genes novel
8

Similar Publications

Characterization of Broad Spectrum Bacteriophage vB ESM-pEJ01 and Its Antimicrobial Efficacy Against Shiga Toxin-Producing in Green Juice.

Microorganisms

January 2025

Department of Food Science and Biotechnology, College of Bionano Technology, Gachon University, Seongnam 13120, Republic of Korea.

Shiga toxin-producing (STEC) infections have increased in humans, animals, and the food industry, with ready-to-eat (RTE) food products being particularly susceptible to contamination. The prevalence of multidrug-resistant strains has rendered the current control strategies insufficient to effectively control STEC infections. Herein, we characterized the newly isolated STEC phage vB_ESM-pEJ01, a polyvalent phage capable of infecting and species, and assessed its efficacy in reducing STEC in vitro and food matrices.

View Article and Find Full Text PDF

Hybrid strains of enterotoxigenic/Shiga toxin-producing , United Kingdom, 2014-2023.

J Med Microbiol

January 2025

NIHR Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, UK.

Diarrhoeagenic (DEC) pathotypes are defined by genes located on mobile genetic elements, and more than one definitive pathogenicity gene may be present in the same strain. In August 2022, UK Health Security Agency (UKHSA) surveillance systems detected an outbreak of hybrid Shiga toxin-producing /enterotoxigenic (STEC-ETEC) serotype O101:H33 harbouring both Shiga toxin () and heat-stable toxin (). These hybrid strains of DEC are a public health concern, as they are often associated with enhanced pathogenicity.

View Article and Find Full Text PDF

In July 2022, a genetically linked and geographically dispersed cluster of 12 cases of Shiga toxin-producing (STEC) O103:H2 was detected by the UK Health Security Agency using whole genome sequencing. Review of food history questionnaires identified cheese (particularly an unpasteurized brie-style cheese) and mixed salad leaves as potential vehicles. A case-control study was conducted to investigate exposure to these products.

View Article and Find Full Text PDF

Shiga toxin-producing Escherichia coli (STEC) infections pose a significant public health challenge, characterized by severe complications including hemolytic uremic syndrome (HUS) due to Shiga toxin (Stx) production. Current therapeutic approaches encounter a critical limitation, as conventional antibiotic treatment is contraindicated due to its propensity to trigger bacterial SOS response and subsequently enhance Stx production, which increases the likelihood of developing HUS in antibiotic-treated patients. The lack of effective, safe therapeutic options has created an urgent need for alternative treatment strategies for STEC infections.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!